Debbie Colangelo Named To JDRF Board of Directors

Jan 26, 2014 No Comments by

Debbie Colangelo, President of CRE-sources, was recently elected to the Board of Directors for the South Florida Chapter of the JDRF (Juvenile Diabetes Research Foundation), the largest charitable supporter of type 1 diabetes research.

Colangelo serves on the Marketing/Communications Committee, where she brings her insight and expertise in advertising, marketing and public relations to the organization.

Colangelo’s oldest daughter, Kristen, was diagnosed with type 1 diabetes (T1D) in 2008, at the age of 10.

“When my daughter was diagnosed, I had NO idea what this disease required: checking blood every 2 hours…day and night, injecting my little girl with insulin up to 6 times a day – sometimes with two different insulins, sometimes one, depending on what time of the day it is, preparing menus and carb counts for 6 meals a day, measuring everything that goes into her mouth. It can and has become completely overwhelming at times,” commented Colangelo.

She continued, “My daughter averages between 90-100 injections every month… far more than any child should have to endure, and knowing this is a disease that she will never outgrow motivated me to do my part in finding a solution.”

JDRF has awarded more than $1.6 billion to diabetes research.  More than 80 percent of JDRF’s expenditures directly support diabetes research.

In 2012, Forbes included JDRF among its Top 5 All-Star Charities: Top Rankings For Efficient Groups, citing the organization’s successful efforts to hold down costs by relying on a network of volunteers–everyone from International Chairman Mary Tyler Moore to “advocates” who lobby Congress for diabetes funding to elementary school kids taking part in the fundraising walks that helped it fund more than $110 million in T1D research.

Jane A “Jan” Nassivera, a Real Estate Consultant in the Fort Lauderdale office of GrayRobinson, P.A., and a former president of the South Florida Chapter of the Juvenile Diabetes Research Foundation, along with Bradley Goodchild II, First Vice President – Investment Officer with Wells Fargo Advisors, have also joined the chapter’s board.

Nassivera served on the Board for several years, including as president from 2003–2005.  Goodchild’s son was diagnosed with T1D in 2011.


About T1D

In T1D, a person’s pancreas stops producing insulin, a hormone that enables people to get energy from food. People with T1D need to test their blood sugar and give themselves insulin (with injections or an insulin pump) multiple times every day, and carefully balance insulin doses with eating and daily activities throughout the day and night. However, insulin is not a cure for diabetes, and even with that intensive care, a significant portion of the day is still spent with either high or low blood sugar, placing people with T1D at risk for devastating complications such as heart attack, stroke, blindness, and amputation.

About JDRF

JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is now the largest charitable supporter of T1D research. The goal of JDRF research is to improve the lives of all people affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal.

Since its founding in 1970, JDRF has awarded more than $1.7 billion to diabetes research. Past JDRF efforts have helped to significantly advance the care of people with this disease, and have expanded the critical scientific understanding of T1D. JDRF will not rest until T1D is fully conquered. More than 80 percent of JDRF’s expenditures directly support research and research-related education.


Go Ahead...Share!
  • email
  • Facebook
  • LinkedIn
  • Twitter
  • Add to favorites
  • Print
Industry News
No Responses to “Debbie Colangelo Named To JDRF Board of Directors”

Leave a Reply